JM Financial ranks hospitals on top as generics face tough two years

November 19, 2025
Uncategorized

Amey Chalke, Pharma Research Analyst at JM Financial Institutional Securities, stays positive on hospitals and believes current high valuations will look reasonable once investors shift focus to FY28 estimates.

JM Financial ranks hospitals on top as generics face tough two years

Leave a ReplyCancel Reply

Dabur India gets ITAT relief as tax demand drops from ₹110 crore to ₹51 crore

Piramal Pharma Solutions’ UK bioconjugates site gets updated MHRA GMP certificates

SpiceJet clears ₹442-crore liability after major restructuring with Carlyle Aviation Partners

JM Financial ranks hospitals on top as generics face tough two years

Copper to reach $13,000/tonne by 2026 end on rising tech demand: Kunal Shah